L. Thomas - Concepedia

Author

L. Thomas

Also Known As

A. Stratigos, L THOMAS, L Thomas, L. THOMAS, L. Thomas, L., Thomas, LF Thomas, LUC THOMAS, Laetitia Thomas, Laëtitia Thomas

816

Publications

38K

Citations

H-Index

313

Concepts

All Affiliations

Université Claude Bernard Lyon 1 Hôpital Lyon Sud Inserm Hospices Civils de Lyon Centre de Recherche en Cancérologie de Lyon

About

L. Thomas is an author at Université Claude Bernard Lyon 1 specializing in medicine, pathology, and dermatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	17	21	4K
2	Engineering	10	10	1.3K
3	Education	8	8	338
4	Arts	1	1	22
5	Business	1	1	12

L. Thomas

279

Publications

34.2K

Citations

H-Index

Page 1

	Year	Citations
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Caroline Robert, L. Thomas, Igor Bondarenko, New England Journal of Medicine	2011	4.4K
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, The Lancet Oncology Checkmate 037MedicineMelanomaNivolumab Versus ChemotherapyImmune Checkpoint Inhibitor	2015	2.6K
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma James Larkin, Paolo A. Ascierto, Brigitte Dréno, New England Journal of Medicine	2014	2K
Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists Holger A. Haenssle, Christine Fink, Roland Schneiderbauer, Annals of Oncology	2018	1.5K
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob, New England Journal of Medicine	2016	1.3K
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Jedd D. Wolchok, Bart Neyns, Gerald P. Linette, The Lancet Oncology Pretreated Advanced MelanomaMedicineMelanomaClinical TrialsIpilimumab Monotherapy	2009	1.2K
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno, The Lancet Oncology MedicineAdvanced Brafv600-mutant MelanomaMelanomaImmune Checkpoint InhibitorDermatology	2016	986
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial Michael A. Davies, Philippe Saïag, Caroline Robert, The Lancet Oncology MedicineMelanomaPathologyImmune Checkpoint InhibitorCancer Treatment	2017	759
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma Corine Bertolotto, Fabienne Lesueur, Sandy Giuliano, Nature Somatic VariantGeneticsMelanomaRenal CarcinomaPathology	2011	513
Comparison of the accuracy of human readers versus machine-learning algorithms for pigmented skin lesion classification: an open, web-based, international, diagnostic study Philipp Tschandl, Noel Codella, Bengü Nisa Akay, The Lancet Oncology Diagnostic StudyEngineeringMachine LearningBiometricsDiagnosis	2019	513

Page 1